Now Antidepressant-Induced Chronic Depression Has a Name: Tardive Dysphoria
Three recently published papers, along with a report by a Minnesota group on health outcomes in that state, provide new reason to mull over...
Drug Companies ‘Just Say No’ to Psych Drugs
The market for psychiatric drugs is, of course, booming. In 2011, spending on psychiatric medications can expect to top $40 billion. Yet, in spite...
”Broken Brains” and “Beautiful Minds”
When I first interviewed Brandon Banks, in the spring of 2008, while researching Anatomy of an Epidemic, he had recently entered Elizabethtown Community College...
Update on the Star*D Report
Two months ago, I wrote a post about a New Yorker article that reported that 67% of the depressed patients in the STAR*D trial...
A Schizophrenia Mystery Solved?
One of the enduring mysteries in schizophrenia research circles has been the disparity in outcomes between schizophrenia patients in "developing countries" and those in...
Antipsychotics/Schizophrenia
The long-term outcomes literature for antipsychotics, which has been compiled over a period of nearly 50 years, consistently tells of drugs that increase the...
Fact Checking the New Yorker, Part Two
In his March 1 article in the New Yorker, Louis Menand wrote that the NIMH's STAR*D trial showed that antidepressants produced a 67% recovery...
Fact Checking the New Yorker
In the March 1 issue of the New Yorker, Louis Menand surveyed the topsy-turvy world of treatments for depression, writing in part of the...